✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Ripretinibis the generic ingredient in one branded drug marketed by Deciphera Pharms and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Ripretinib has sixty-one patent family members in thirteen countries.
One supplier is listed for this compound.
Summary for ripretinib
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||24|
|What excipients (inactive ingredients) are in ripretinib?||ripretinib excipients list|
|DailyMed Link:||ripretinib at DailyMed|
Recent Clinical Trials for ripretinib
Identify potential brand extensions & 505(b)(2) entrants
|Theseus Pharmaceuticals||Phase 1/Phase 2|
|Deciphera Pharmaceuticals LLC||Phase 1/Phase 2|
Pharmacology for ripretinib
|Drug Class|| Kinase Inhibitor |
|Mechanism of Action||Breast Cancer Resistance Protein Inhibitors |
Cytochrome P450 2C8 Inhibitors
Platelet-derived Growth Factor alpha Receptor Inhibitors
Stem Cell Factor (KIT) Receptor Inhibitors
|Company||Drugname||Inn||Product Number / Indication||Status||Generic||Biosimilar||Orphan||Marketing Authorisation||Marketing Refusal|
|Deciphera Pharmaceuticals (Netherlands) B.V.||Qinlock||ripretinib||EMEA/H/C/005614
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
|>Company||>Drugname||>Inn||>Product Number / Indication||>Status||>Generic||>Biosimilar||>Orphan||>Marketing Authorisation||>Marketing Refusal|
|Country||Patent Number||Title||Estimated Expiration|
|Australia||2020417282||Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea||See Plans and Pricing|
|China||115135308||非晶型激酶抑制剂制剂及其使用方法||See Plans and Pricing|
|Argentina||122355||COMPOSICIONES DE 1-(4-BROMO-5-(1-ETIL-7-(METILAMINO)-2-OXO-1,2- DIHIDRO-1,6-NAFTIRIDIN-3-YL)-2-FLUOROFENIL)-3-FENILUREA||See Plans and Pricing|
|South Korea||20090067175||KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES||See Plans and Pricing|
|South Korea||101110530||See Plans and Pricing|
|European Patent Office||2063897||INHIBITEURS DE KINASES UTILES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES (KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES)||See Plans and Pricing|
|China||101516379||Kinase inhibitors useful for the treatment of proliferative diseases||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.